Medical Reports & Case Studies

Targeted Chemotherapy via Folic Acid Decorated Nano Medicines

Stella Princeton^{* *}Correspondence: Stella Princeton, Editorial Office, Medical Reports and Case Studies, France, Email:

Author info »

Perspective

Each year, seasonal influenza claims the lives of between 250,000 and Cancer is one of the leading causes of death worldwide, and its prevalence continues to rise. Traditional cancer treatments, such as chemotherapy and radiation therapy, can cause significant side effects, and often have limited efficacy. In recent years, there has been significant interest in developing more targeted and effective cancer treatments using nanotechnology.

One promising approach is the use of folic acid decorated nanomedicines for targeted chemotherapy. Folic acid is a vitamin that is essential for cell growth and division. Many cancer cells overexpress folate receptors, which allows them to take up more folic acid than normal cells. By attaching folic acid to nanoparticles that contain chemotherapy drugs, it is possible to target cancer cells specifically and deliver drugs directly to them, while sparing healthy cells. Nanoparticles are extremely small particles, typically in the range of 1 to 100 nanometers. At this size, they can penetrate deeply into tissues and cells, making them an ideal vehicle for drug delivery. Nanoparticles can also be engineered to release drugs slowly over time, which can improve their efficacy and reduce side effects.

One type of nanoparticle that has shown promise for targeted chemotherapy is the liposome. Liposomes are small spherical structures made of lipids, which are natural building blocks of cell membranes. Liposomes can encapsulate a variety of drugs, including chemotherapy agents, and can be decorated with molecules such as folic acid to target cancer cells specifically.

Several studies have shown the potential of folic acid decorated liposomes for targeted chemotherapy. For example, one study published in the journal Cancer Research showed that folic acid decorated liposomes containing the chemotherapy drug paclitaxel were able to reduce tumor growth in mice with ovarian cancer. The liposomes were shown to accumulate specifically in the tumor tissue, and were more effective at reducing tumor growth than untargeted liposomes containing paclitaxel.

Another study published in the journal Biomaterials showed that folic acid decorated liposomes containing the chemotherapy drug doxorubicin were able to reduce tumor growth in mice with breast cancer. The liposomes were shown to accumulate specifically in the tumor tissue, and were more effective at reducing tumor growth than untargeted liposomes containing doxorubicin. In addition to liposomes, other types of nanoparticles have also been investigated for targeted chemotherapy using folic acid decoration. For example, polymeric nanoparticles, which are made of synthetic polymers, have been used to deliver chemotherapy drugs to cancer cells. These nanoparticles can also be decorated with folic acid to target cancer cells specifically. One study published in the journal Biomaterials showed that folic acid decorated polymeric nanoparticles containing the chemotherapy drug docetaxel were able to reduce tumor growth in mice with lung cancer. The nanoparticles were shown to accumulate specifically in the tumor tissue, and were more effective at reducing tumor growth than untargeted polymeric nanoparticles containing docetaxel.

Despite the promising results of these studies, there are still some challenges that need to be addressed before folic acid decorated nanomedicines can be used in clinical practice. One challenge is ensuring that the nanoparticles are able to penetrate the tumor tissue and reach the cancer cells. This can be difficult, as tumors are often surrounded by a dense extracellular matrix that can prevent nanoparticles from entering. Researchers are exploring ways to modify the surface of nanoparticles to improve their ability to penetrate tumor tissue. Another challenge is ensuring that the nanoparticles are not taken up by healthy cells, as this can lead to off-target effects and toxicity. Researchers are exploring ways to further optimize the surface decoration of nanoparticles to improve their specificity for cancer cells.

Chemotherapy has been an important part of cancer treatment for decades, but it comes with a variety of side effects due to its non-specific nature. Chemotherapy targets both cancerous and healthy cells, resulting in a host of unpleasant side effects such as nausea, hair loss, and weakened immune systems. However, recent advances in nanotechnology have opened up the possibility of targeted chemotherapy, which could reduce the impact of side effects by specifically targeting cancer cells. One promising approach is the use of folic acid-decorated nanomedicines, which have been shown to selectively deliver chemotherapy drugs to cancer cells with high levels of folate receptors.

Folate, or vitamin B9, is an essential nutrient that plays a key role in many biological processes, including DNA synthesis and repair. Cancer cells often have an increased demand for folate due to their rapid proliferation rate, which leads to an upregulation of folate receptors on the cell surface. This provides an opportunity to target cancer cells specifically by using folic acid as a targeting ligand.

Folic acid-decorated nanomedicines are typically composed of a nanoparticle core that is coated with a layer of folic acid molecules. The nanoparticle core can be made from a variety of materials, including lipids, polymers, and metals, and can be loaded with a variety of chemotherapy drugs. The folic acid molecules on the surface of the nanoparticle act as a homing device, binding specifically to folate receptors on the surface of cancer cells.

Once the folic acid-decorated nanomedicine has bound to the cancer cell, the nanoparticle can be internalized via receptor-mediated endocytosis. This process involves the formation of a vesicle, or endosome, around the nanoparticle, which is then transported to the interior of the cell. Once inside the cell, the endosome can fuse with a lysosome, which contains enzymes that can break down the nanoparticle and release the chemotherapy drug. The chemotherapy drug can then act on the cancer cell, causing cell death or inhibiting cell proliferation.

The use of folic acid-decorated nanomedicines has several advantages over traditional chemotherapy. Firstly, the specific targeting of cancer cells means that the chemotherapy drug is delivered directly to the cancerous tissue, reducing the impact on healthy tissues and reducing side effects. Secondly, the use of nanomedicines allows for the delivery of higher doses of chemotherapy drugs, which can be more effective at killing cancer cells. Finally, the use of nanomedicines can improve the pharmacokinetics of the chemotherapy drug, allowing for a longer circulation time in the body and a greater accumulation in the cancerous tissue.

One example of a folic acid-decorated nanomedicine that has shown promise in preclinical studies is Doxil, a liposomal formulation of the chemotherapy drug doxorubicin. Doxil is composed of a lipid bilayer that encases a central aqueous compartment containing doxorubicin. The lipid bilayer is decorated with Polyethylene Glycol (PEG) to increase circulation time in the body and folic acid molecules for targeted delivery to cancer cells. Doxil has been shown to be effective in a variety of cancers, including ovarian and breast cancer, and has a lower incidence of side effects compared to traditional chemotherapy with doxorubicin. In conclusion, folate-decorated nanomedicines represent a promising approach for targeted chemotherapy. By specifically targeting cancer cells that overexpress the FR, these nanomedicines can improve drug efficacy and reduce side effects. While there are still challenges to be overcome in the development and production of these nanomedicines, their potential benefits make them an exciting area of research in the fight against cancer.